Peripheral Neuropathy Trial, Recruiting (NCT06774989)

Peripheral Neuropathy Trial, Recruiting NCT06774989 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT06774989 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed with advanced melanoma (a type of skin cancer) at stage III or stage IV that cannot be surgically removed, including melanoma that started in the skin, in mucous membranes (such as the mouth or nose), or from an unknown location — confirmed by laboratory testing of tissue
People who are being treated with the medications encorafenib and/or binimetinib, at any stage of their treatment, with the aim of treating their cancer
People who are covered by, or eligible under, a social security or health insurance scheme
People who have been informed about the trial and have not objected to taking part

Who may not be able to join:

No specific exclusion criteria have been listed for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Elisa FUNCK-BRETANO, MD, PhD, Department of Oncology-Dermatology, Ambroise Paré Hospital - APHP

Phone: + 33171167721

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06774989

Sponsor: Assistance Publique - Hôpitaux de Paris

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: + 33171167721

More information: https://clinicaltrials.gov/study/NCT06774989

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 years or older
People who have been diagnosed with advanced melanoma (a type of skin cancer) at stage III or stage IV that cannot be surgically removed, including melanoma that started in the skin, in mucous membranes (such as the mouth or nose), or from an unknown location — confirmed by laboratory testing of tissue
People who are being treated with the medications encorafenib and/or binimetinib, at any stage of their treatment, with the aim of treating their cancer
People who are covered by, or eligible under, a social security or health insurance scheme
People who have been informed about the trial and have not objected to taking part

Who may not be able to join:

No specific exclusion criteria have been listed for this trial (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Assistance Publique - Hôpitaux de Paris

Registry

ClinicalTrials.gov

Start date

2 January 2025

Est. completion

1 January 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

association between the plasma exposure of encorafenib and binimetinib and the occurrence of dose-limiting toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov